Valuation : Acrux Limited

Market Cap 6.49M 4.65M 4.01M 3.8M 3.44M 6.45M 444M 45.08M 17.33M 226M 17.47M 17.09M 714M P/E 2025
-0.95x
P/E 2026 -8.4x
Enterprise Value 7.3M 5.24M 4.51M 4.27M 3.87M 7.26M 500M 50.73M 19.51M 254M 19.66M 19.23M 804M EV / Sales 2025
2.07x
EV / Sales 2026 1.08x
Free-Float
95.37%
Yield 2025 *
-
Yield 2026 -

Last Transcript : Acrux Limited

Current month+4.76%
1 month+22.22%
3 months-35.29%
6 months-15.38%
Current year-26.67%
1 week 0.01
Extreme 0.01
0.01
1 month 0.01
Extreme 0.009
0.01
Current year 0.01
Extreme 0.009
0.02
1 year 0.01
Extreme 0.009
0.02
3 years 0.01
Extreme 0.009
0.1
5 years 0.01
Extreme 0.009
0.14
10 years 0.01
Extreme 0.009
0.38
Manager TitleAgeSince
Chief Executive Officer - 01/06/2025
Director of Finance/CFO - 21/06/2021
Chief Tech/Sci/R&D Officer - 24/08/2026
Director TitleAgeSince
Chairman 74 01/01/2006
Director/Board Member - 01/10/2013
Director/Board Member 70 01/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-24.14%-74.42% 4.65M
-1.13%-3.11%+13.82%+60.66% 46.21B
-1.13%-5.78%+33.26%+108.13% 38.78B
+0.12%-0.08%+7.12%+78.27% 11.68B
-0.53%-1.37%-13.25%+10.18% 11.55B
-0.38%-2.26%+18.18%+139.63% 9.14B
+0.32%-2.26%+23.08%+34.73% 7.3B
+0.17%-0.74%+13.44%+197.13% 7.15B
-1.00%-5.25%+34.34%-19.63% 7.1B
-3.13%-4.30%-44.88%+11.66% 4.97B
Average -0.67%-2.33%+6.10%+54.64% 14.39B
Weighted average by Cap. -0.86%-3.27%+16.05%+75.65%

Financials

2025 2026
Net sales 4.49M 3.22M 2.77M 2.63M 2.38M 4.47M 308M 31.19M 11.99M 156M 12.09M 11.82M 494M 6.58M 4.72M 4.07M 3.85M 3.49M 6.55M 451M 45.73M 17.59M 229M 17.73M 17.34M 725M
Net income -5.94M -4.26M -3.67M -3.48M -3.15M -5.92M -407M -41.31M -15.89M -207M -16.01M -15.66M -655M -604K -433K -373K -353K -320K -601K -41.39M -4.2M -1.61M -21.05M -1.63M -1.59M -66.53M
Net Debt 2.77M 1.99M 1.71M 1.62M 1.47M 2.76M 190M 19.26M 7.41M 96.63M 7.47M 7.3M 305M 813K 583K 502K 476K 431K 809K 55.71M 5.65M 2.17M 28.34M 2.19M 2.14M 89.55M
Logo Acrux Limited
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Employees
43
Date Price Change Volume
09/09/26 A$0.0110 0.00% 2,843,866
08/09/26 A$0.0110 0.00% 388,905

Annual profits - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!